Biomarker testing in lung carcinoma cytology specimens

A perspective from members of the Pulmonary Pathology Society

Sinchita Roy-Chowdhuri, Dara L. Aisner, Timothy Craig Allen, Mary Beth Beasley, Alain Borczuk, Philip T. Cagle, Vera Capelozzi, Sanja Dacic, Gilda Da Cunha Santos, Lida P. Hariri, Keith M. Kerr, Sylvie Lantuejoul, Mari Mino-Kenudson, Andre Moreira, Kirtee Raparia, Natasha Rekhtman, Lynette Sholl, Eric Thunnissen, Ming Sound Tsao, Marina Vivero & 1 others Yasushi Yatabe

Research output: Contribution to journalReview article

50 Citations (Scopus)

Abstract

The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.

Original languageEnglish (US)
Pages (from-to)1267-1272
Number of pages6
JournalArchives of Pathology and Laboratory Medicine
Volume140
Issue number11
DOIs
StatePublished - Nov 1 2016

Fingerprint

Cell Biology
Lung Neoplasms
Biomarkers
Pathology
Carcinoma
Lung
Triage
Therapeutics

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Roy-Chowdhuri, S., Aisner, D. L., Allen, T. C., Beasley, M. B., Borczuk, A., Cagle, P. T., ... Yatabe, Y. (2016). Biomarker testing in lung carcinoma cytology specimens: A perspective from members of the Pulmonary Pathology Society. Archives of Pathology and Laboratory Medicine, 140(11), 1267-1272. https://doi.org/10.5858/arpa.2016-0091-SA

Biomarker testing in lung carcinoma cytology specimens : A perspective from members of the Pulmonary Pathology Society. / Roy-Chowdhuri, Sinchita; Aisner, Dara L.; Allen, Timothy Craig; Beasley, Mary Beth; Borczuk, Alain; Cagle, Philip T.; Capelozzi, Vera; Dacic, Sanja; Da Cunha Santos, Gilda; Hariri, Lida P.; Kerr, Keith M.; Lantuejoul, Sylvie; Mino-Kenudson, Mari; Moreira, Andre; Raparia, Kirtee; Rekhtman, Natasha; Sholl, Lynette; Thunnissen, Eric; Tsao, Ming Sound; Vivero, Marina; Yatabe, Yasushi.

In: Archives of Pathology and Laboratory Medicine, Vol. 140, No. 11, 01.11.2016, p. 1267-1272.

Research output: Contribution to journalReview article

Roy-Chowdhuri, S, Aisner, DL, Allen, TC, Beasley, MB, Borczuk, A, Cagle, PT, Capelozzi, V, Dacic, S, Da Cunha Santos, G, Hariri, LP, Kerr, KM, Lantuejoul, S, Mino-Kenudson, M, Moreira, A, Raparia, K, Rekhtman, N, Sholl, L, Thunnissen, E, Tsao, MS, Vivero, M & Yatabe, Y 2016, 'Biomarker testing in lung carcinoma cytology specimens: A perspective from members of the Pulmonary Pathology Society', Archives of Pathology and Laboratory Medicine, vol. 140, no. 11, pp. 1267-1272. https://doi.org/10.5858/arpa.2016-0091-SA
Roy-Chowdhuri, Sinchita ; Aisner, Dara L. ; Allen, Timothy Craig ; Beasley, Mary Beth ; Borczuk, Alain ; Cagle, Philip T. ; Capelozzi, Vera ; Dacic, Sanja ; Da Cunha Santos, Gilda ; Hariri, Lida P. ; Kerr, Keith M. ; Lantuejoul, Sylvie ; Mino-Kenudson, Mari ; Moreira, Andre ; Raparia, Kirtee ; Rekhtman, Natasha ; Sholl, Lynette ; Thunnissen, Eric ; Tsao, Ming Sound ; Vivero, Marina ; Yatabe, Yasushi. / Biomarker testing in lung carcinoma cytology specimens : A perspective from members of the Pulmonary Pathology Society. In: Archives of Pathology and Laboratory Medicine. 2016 ; Vol. 140, No. 11. pp. 1267-1272.
@article{3441b7792d5c49648dda802d282e6d95,
title = "Biomarker testing in lung carcinoma cytology specimens: A perspective from members of the Pulmonary Pathology Society",
abstract = "The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.",
author = "Sinchita Roy-Chowdhuri and Aisner, {Dara L.} and Allen, {Timothy Craig} and Beasley, {Mary Beth} and Alain Borczuk and Cagle, {Philip T.} and Vera Capelozzi and Sanja Dacic and {Da Cunha Santos}, Gilda and Hariri, {Lida P.} and Kerr, {Keith M.} and Sylvie Lantuejoul and Mari Mino-Kenudson and Andre Moreira and Kirtee Raparia and Natasha Rekhtman and Lynette Sholl and Eric Thunnissen and Tsao, {Ming Sound} and Marina Vivero and Yasushi Yatabe",
year = "2016",
month = "11",
day = "1",
doi = "10.5858/arpa.2016-0091-SA",
language = "English (US)",
volume = "140",
pages = "1267--1272",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "11",

}

TY - JOUR

T1 - Biomarker testing in lung carcinoma cytology specimens

T2 - A perspective from members of the Pulmonary Pathology Society

AU - Roy-Chowdhuri, Sinchita

AU - Aisner, Dara L.

AU - Allen, Timothy Craig

AU - Beasley, Mary Beth

AU - Borczuk, Alain

AU - Cagle, Philip T.

AU - Capelozzi, Vera

AU - Dacic, Sanja

AU - Da Cunha Santos, Gilda

AU - Hariri, Lida P.

AU - Kerr, Keith M.

AU - Lantuejoul, Sylvie

AU - Mino-Kenudson, Mari

AU - Moreira, Andre

AU - Raparia, Kirtee

AU - Rekhtman, Natasha

AU - Sholl, Lynette

AU - Thunnissen, Eric

AU - Tsao, Ming Sound

AU - Vivero, Marina

AU - Yatabe, Yasushi

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.

AB - The advent of targeted therapy in lung cancer has heralded a paradigm shift in the practice of cytopathology with the need for accurately subtyping lung carcinoma, as well as providing adequate material for molecular studies, to help guide clinical and therapeutic decisions. The variety and versatility of cytologic-specimen preparations offer significant advantages to molecular testing; however, they frequently remain underused. Therefore, evaluating the utility and adequacy of cytologic specimens is critical, not only from a lung cancer diagnosis standpoint but also for the myriad ancillary studies that are necessary to provide appropriate clinical management. A large fraction of lung cancers are diagnosed by aspiration or exfoliative cytology specimens, and thus, optimizing strategies to triage and best use the tissue for diagnosis and biomarker studies forms a critical component of lung cancer management. This review focuses on the opportunities and challenges of using cytologic specimens for molecular diagnosis of lung cancer and the role of cytopathology in the molecular era.

UR - http://www.scopus.com/inward/record.url?scp=84992672556&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992672556&partnerID=8YFLogxK

U2 - 10.5858/arpa.2016-0091-SA

DO - 10.5858/arpa.2016-0091-SA

M3 - Review article

VL - 140

SP - 1267

EP - 1272

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 11

ER -